<DOC>
	<DOCNO>NCT02699840</DOCNO>
	<brief_summary>The aim study generate local data safety Menactra® individual 2 55 year age Russian Federation . Primary Objective : - To describe safety profile 1 dose Menactra® administer individual 2-55 year age standard health care practice .</brief_summary>
	<brief_title>Observational Safety Study Menactra® Administered Under Standard Health Care Practice Russian Federation</brief_title>
	<detailed_description>Participants enrol receipt one dose Menactra® routine health care visit . They monitor safety throughout study .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 55 year day enrollment `` 2 55 year '' mean day 2nd birthday day 56th birthday For adult ( 1855 year old ) Informed consent form sign dated participant . For minor : Informed consent form sign dated parent . In addition , accordance Institution Ethics Committee/Institution Review Board requirement appropriate age participant : participant age 14 17 year require sign date inform consent form , participant age 10 13 year require sign date assent form , participant 10 year , consent may ask orally accord participant 's age ability understand Receipt one dose Menactra® day inclusion prior enrollment study , routine practice accord approve local product insert . Participation time study enrollment ( 4 week precede enrollment ) plan participation present study period clinical study investigate vaccine , drug , medical device , medical procedure .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Meningococcal Vaccine</keyword>
</DOC>